Stub
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the Ontology.
CE & Ipilimumab
back to top |
CE & Ipilimumab: Carboplatin, Etoposide, Ipilimumab
Regimen
Chemotherapy
Immunotherapy
CE & Thalidomide
back to top |
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
EP & Ipilimumab
back to top |
EP & Ipilimumab: Etoposide, Platinol (Cisplatin), Ipilimumab
Regimen
Chemotherapy
Immunotherapy
EP, Tamoxifen, RT
back to top |
EP, GM-CSF, RT: Etoposide, Platinol (Cisplatin), Tamoxifen, Radiation Therapy
Regimen
Chemotherapy
Hormonotherapy
Radiotherapy
- Concurrent thoracic radiation therapy
FULV & Trimetrexate
back to top |
FULV & Trimetrexate: 5-FU & LeucoVorin (Folinic acid), Trimetrexate
Regimen
Chemotherapy
Ixabepilone & Bevacizumab
back to top |
Regimen
Chemotherapy
Targeted therapy
TG+Bev
back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TX+Bev
back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab